SEC Form 4 · accession 0001140361-17-015056
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A. Lewicki
Officer — EVP, Research & Development
Period of report
Apr 4, 2017
Accepted (ET)
Apr 5, 2017 · 7:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F4 | Apr 4, 2017 | S | 43 | $8.8671 | D | 28,648 | D | |
| Common StockF2,F3,F4 | Apr 4, 2017 | S | 5,711 | $9.0582 | D | 22,937 | D | |
| Common StockF4,F5 | holding | — | — | — | 88,951 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes.
- F2Includes 12,500 restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
- F3Includes 1,191 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017.
- F4Reflects an aggregate of 4,136 shares the Reporting Person previously transferred to his family trust.
- F5The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000.